CJC-1295

CJC-1295 is a synthetic analog of human growth-hormone-releasing hormone (GHRH), engineered from the biologically active 29-amino-acid fragment of the natural hormone, GHRH(1-29), with amino acid substitutions designed to resist the rapid enzymatic degradation that limits native GHRH to a half-life of only a few minutes in the bloodstream. It was developed in the early 2000s by ConjuChem, a Montreal-based biotechnology company, which additionally applied a proprietary technology called Drug Affinity Complex (DAC) to a version of the molecule, chemically attaching a reactive linker that forms a covalent bond with circulating serum albumin. This albumin-binding modification converts the peptide from a short-lived free molecule into a long-lived, slowly released albumin-bound depot, extending its effective duration of action from roughly 30 minutes to an estimated 6 to 8 days. Two distinct products consequently circulate under the CJC-1295 name: "CJC-1295 with DAC," carrying this long-acting modification, and "CJC-1295 without DAC" (also sold as Mod GRF 1-29), which retains the degradation-resistant backbone but lacks the albumin-binding group and is correspondingly short-acting. ConjuChem discontinued its own clinical development of CJC-1295 after early human trials, and no other pharmaceutical sponsor has since advanced it to a confirmatory efficacy trial or regulatory approval for any indication; it exists today almost exclusively as a compounded and research-chemical product.

The core mechanism of CJC-1295, in either form, is activation of the growth-hormone-releasing hormone receptor (GHRHR) on pituitary somatotroph cells, the same receptor that endogenous GHRH activates to stimulate synthesis and pulsatile release of growth hormone. This mechanism is distinct from that of ghrelin-receptor (GHSR-1a) agonists such as ipamorelin, which act on a separate receptor and signaling pathway on the same somatotroph cells; the two classes are considered pharmacologically complementary, providing the physiological rationale for compounding a GHRH analog together with a GHRP to produce a larger combined growth hormone pulse. Downstream of GHRHR activation, growth hormone acts on the growth hormone receptor (GHR) in the liver and peripheral tissues to stimulate production of insulin-like growth factor 1 (IGF-1), the hormone mediating most of growth hormone's anabolic and tissue-building effects; GH1, GHR, and IGF1 together form the signaling axis that CJC-1295 engages indirectly through its action at the pituitary receptor. A key mechanistic finding from the available human trial data is that CJC-1295 with DAC preserves the normal pulsatile pattern of growth hormone secretion despite producing a sustained elevation in mean hormone levels over days, rather than converting secretion into continuous, non-pulsatile release, a distinction considered physiologically favorable because animal studies have linked sustained non-pulsatile growth hormone exposure to reduced receptor sensitivity over time.

The human evidence base for CJC-1295 rests almost entirely on a single 2006 randomized, placebo-controlled, dose-escalation trial in healthy adults and a companion analysis of the same trial data. The primary trial found that a single subcutaneous dose of CJC-1295 with DAC produced a dose-dependent rise in growth hormone and IGF-1 that remained elevated for 6 to 9 days, and that repeated dosing every 7 or 14 days maintained elevated IGF-1 levels throughout a 28-day observation period. The companion analysis confirmed that this sustained elevation preserved rather than eliminated the normal pulsatile secretion pattern of growth hormone. These findings are pharmacodynamic, measuring blood hormone levels in healthy volunteers over a short observation window; no trial has measured body composition, strength, exercise performance, sleep quality, or any other clinical or functional outcome after CJC-1295 administration, whether in the DAC or non-DAC form, and no dedicated human trial of the non-DAC form has been published at all. This is the central honest gap in the CJC-1295 evidence base: a well-characterized short-term hormonal effect with essentially no data on the downstream outcomes for which it is marketed.

From a pharmacokinetic and regulatory standpoint, CJC-1295 is given exclusively by subcutaneous injection and is not orally bioavailable. The DAC-modified form has an estimated half-life of 6 to 8 days, enabling weekly to twice-weekly compounded dosing, while the non-DAC form has an estimated half-life of only about 30 minutes, requiring multiple daily injections in compounding practice; this large difference in duration is the main practical distinction users and compounders draw between the two forms. Neither form is approved by the FDA, EMA, or any other regulatory authority for any indication; ConjuChem abandoned the compound clinical development program, and it exists today almost exclusively through compounding pharmacies operating under varying degrees of regulatory oversight and through research-chemical vendors selling it labeled "for research use only." Independent testing initiatives evaluating research-market peptides have repeatedly found purity, concentration, and labeling inconsistencies across vendors, a quality-control concern layered on top of the underlying efficacy uncertainty. Growth hormone secretagogues as a class, including CJC-1295, are included on the World Anti-Doping Agency prohibited list, making its use a doping violation in tested competitive sport.

Mechanism of Action

GHRH Receptor Activation and the Design Problem of Native GHRH Instability

CJC-1295 is built on the biologically active 29-amino-acid fragment of human growth-hormone-releasing hormone, GHRH(1-29), which binds and activates the growth-hormone-releasing hormone receptor (GHRHR) on pituitary somatotroph cells to trigger synthesis and pulsatile release of growth hormone. Native GHRH, however, is degraded within minutes in human plasma, primarily through cleavage at its amino terminus by dipeptidyl peptidase-4 and other proteases, a limitation that has been characterized since the 1980s and that makes unmodified GHRH impractical as an injectable therapy requiring anything less than near-continuous infusion. CJC-1295 carries amino acid substitutions relative to native GHRH(1-29) specifically engineered to resist this degradation pathway, extending the biologically active lifetime of the free peptide well beyond that of the native hormone even before any additional modification is applied.

The Drug Affinity Complex and Albumin Binding

The version of the molecule known as CJC-1295 with DAC carries an additional modification: a maleimidopropionic acid reactive group attached to the peptide backbone that forms a covalent bond with a free cysteine residue on circulating serum albumin, the most abundant protein in blood plasma. This chemistry, developed by ConjuChem under the name Drug Affinity Complex, converts the peptide from a short-lived free molecule into an albumin-bound depot that circulates with the same slow turnover as albumin itself, extending the peptide’s effective half-life from an estimated 30 minutes in the unmodified form to approximately 6 to 8 days once bound. Because the peptide is released gradually as the albumin-peptide conjugate is metabolized, growth hormone release is stimulated over days rather than in a single sharp pulse, producing the sustained hormone elevation observed in the available human trial.

Preservation of Pulsatile Secretion

A specific mechanistic concern with any long-acting growth hormone secretagogue is whether sustained receptor stimulation converts the body’s normal pulsatile pattern of growth hormone secretion, thought to be important for many of the hormone’s downstream signaling effects, into continuous, non-pulsatile release, which animal studies have associated with reduced growth hormone receptor sensitivity over time. A dedicated analysis of the 2006 human trial data addressed this question directly and found that despite the sustained elevation in mean growth hormone concentration produced by CJC-1295 with DAC, the underlying pulsatile secretion pattern was preserved rather than replaced by flat, continuous secretion, a reassuring finding for the compound’s proposed mechanism, though based on a single small trial.

Downstream GH/IGF-1 Axis Signaling

Growth hormone released in response to CJC-1295 acts on growth hormone receptors (GHR) in the liver and peripheral tissues, activating JAK2/STAT5 and phosphoinositide 3-kinase/AKT signaling that stimulates hepatic and local production of insulin-like growth factor 1 (IGF-1), the hormone that mediates most of growth hormone’s anabolic and tissue-building effects. IGF-1 elevation was the principal pharmacodynamic endpoint used in the 2006 human trial to demonstrate prolonged biological activity of CJC-1295 with DAC and remains the laboratory marker most commonly used to assess ongoing biological effect in research and compounding practice.

Complementary Mechanism with GHRP-Class Secretagogues

CJC-1295 acts exclusively through the GHRH receptor and has no direct activity at the growth hormone secretagogue receptor (GHSR-1a), the ghrelin receptor targeted by GHRP-class compounds such as ipamorelin. Because these two receptor classes engage distinct intracellular signaling pathways in the somatotroph that converge on the same growth-hormone-releasing outcome, they are considered pharmacologically complementary, providing the physiological rationale for compounding CJC-1295 together with a GHRP to produce a larger combined growth hormone pulse than either compound alone. This additive physiology has support from studies of other GHRH/GHRP pairs, but the specific combination of CJC-1295 with a particular GHRP has not itself been tested in a published human trial.

Clinical Evidence

The Pivotal 2006 Dose-Escalation Trial

The primary human evidence for CJC-1295 comes from a single randomized, placebo-controlled, dose-escalation trial published in 2006, conducted in healthy adult volunteers and testing CJC-1295 with DAC. A single subcutaneous injection produced a dose-dependent rise in growth hormone that remained elevated for 6 to 9 days, and repeated dosing every 7 or 14 days maintained elevated IGF-1 levels throughout the 28-day study period. This trial established both the sustained pharmacodynamic effect and the general safety and tolerability of CJC-1295 with DAC at the doses and duration tested, but it measured only blood hormone levels in healthy volunteers, not any clinical, functional, or body-composition outcome.

Pulsatility Analysis

A companion paper published the same year, drawing on the same trial dataset, analyzed the pattern of growth hormone secretion in detail and found that CJC-1295 with DAC preserved the body’s normal pulsatile secretion rhythm rather than converting it to continuous, non-pulsatile release. This finding addressed a specific physiological concern relevant to long-acting secretagogues and remains, alongside the primary dose-escalation trial, one of only two published human studies of CJC-1295.

Absence of Human Data for the Non-DAC Form

CJC-1295 without DAC, despite being widely sold and used in compounding contexts specifically because of its shorter, more titratable duration of action, has not been the subject of any dedicated published human pharmacokinetic or pharmacodynamic trial. Its expected half-life of approximately 30 minutes and its dosing conventions are inferred from its structural similarity to other short-acting GHRH(1-29) analogs, such as sermorelin, rather than from compound-specific human data.

Human Evidence Gap for Body Composition and Downstream Clinical Claims

Neither the 2006 dose-escalation trial nor any subsequent published study has measured body composition, muscle mass, fat mass, exercise performance, sleep quality, or any anti-aging outcome after CJC-1295 administration, in either the DAC or non-DAC form. The extensive marketing of CJC-1295 for these outcomes rests entirely on extrapolation from the observed hormone-level changes and from general physiological reasoning about growth hormone and IGF-1, not on any peptide-specific efficacy trial. This is the most important honest limitation of the CJC-1295 evidence base and applies with equal force to both forms of the compound.

Safety and Tolerability

In the 2006 trial, CJC-1295 with DAC was generally well tolerated at the doses and duration studied, with injection-site reactions being the most commonly reported adverse effect, consistent with subcutaneously administered peptides generally. No serious drug-related adverse events were reported within the 28-day trial period. Systematic long-term safety data, including effects on glucose metabolism, pituitary sensitivity to repeated stimulation, or malignancy risk with chronic elevated IGF-1 exposure, have not been generated in any trial extending beyond this short observation window, and no human safety data exist for CJC-1295 without DAC at all.

Regulatory Status

CJC-1295, in both the DAC and non-DAC forms, is not approved by the United States Food and Drug Administration, the European Medicines Agency, or any other national regulatory authority for any indication. ConjuChem, the company that engineered the compound and its Drug Affinity Complex technology, discontinued its own clinical development program after the initial human trials, and no subsequent sponsor has advanced CJC-1295 itself through a pivotal efficacy trial. It is not a dietary supplement and has no legitimate over-the-counter regulatory pathway. In practice, CJC-1295 is available almost exclusively through compounding pharmacies, which operate under varying degrees of regulatory oversight depending on jurisdiction, and through unregulated research-chemical vendors selling it labeled “for research use only” and not for human consumption. Independent testing initiatives evaluating research-market peptides have repeatedly found purity, concentration, and labeling inconsistencies across vendors. Growth hormone secretagogues as a class, including CJC-1295, are included on the World Anti-Doping Agency prohibited list, making its use a doping violation in tested competitive sport.

CJC-1295 versus Tesamorelin and Sermorelin

CJC-1295, tesamorelin, and sermorelin are all GHRH(1-29)-based analogs acting on the same GHRHR target, but they diverge sharply in regulatory and evidence status. Tesamorelin advanced through a full phase 3 program and gained FDA approval for HIV-associated lipodystrophy, giving it by far the strongest human evidence base of the three. Sermorelin was formerly FDA-approved for pediatric growth hormone deficiency evaluation before being withdrawn from the market for commercial reasons, leaving a smaller but real historical approval record. CJC-1295, by contrast, never advanced beyond a single small dose-escalation trial and a companion pulsatility analysis, both conducted in healthy adults rather than a patient population with a defined disease, and its original developer discontinued the program entirely. Its principal technical distinction from the other two, the DAC-mediated multi-day half-life, is a genuine pharmacokinetic advantage that neither tesamorelin nor sermorelin shares, but that advantage has never been leveraged in a confirmatory efficacy trial.

Dosing Guidance

No dose of CJC-1295, in either form, has been established as safe or effective for chronic administration in a completed human efficacy trial. The only human dosing data come from the 2006 dose-escalation trial of CJC-1295 with DAC, which used single and repeated (every 7 or 14 days) subcutaneous doses over a 28-day observation period to characterize the hormone-level response, not a therapeutic regimen. Compounding-market protocols commonly describe CJC-1295 with DAC doses around 1 to 2 milligrams once weekly to once every two weeks, and CJC-1295 without DAC doses around 100 micrograms one to three times daily, often paired with a GHRP such as ipamorelin, but these figures reflect compounding-pharmacy and vendor convention rather than a validated clinical dosing standard, and should be read strictly as a description of common practice, not a recommendation.